Who has decided the rules on access?
The 10th International Conference of Drug Regulatory Authorities (ICDRA) in Hong Kong 2002 recommended that the utility of the WHO adverse reactions database be strengthened by “opening access to the WHO database to all stakeholders with a genuine public health interest and the ability to evaluate such case information” (see WHO Drug Information 16(3) 219 (2002)). The ability to evaluate such case information will normally be interpreted as anyone with a degree level health professional education (e.g. physician, dentist, nurse, pharmacist). All information provided to inquirers other than the National Centres participating in the WHO International Drug Monitoring Programme, will be accompanied by a Caveat Document. The Caveat Document currently in use was adopted by the meeting of representatives of National Centres in 1989.
